Molecular librarians create druglike collections


Finding biologically active small molecules with pharmaceutical potential is a bittersweet process. Now, a new approach to building libraries of diverse alkaloid-type structures has been developed by US chemists.

scaffold structures

The library is based on a selection of cut-down alkaloid-based molecular scaffolds

Jeffrey Aubé of the University of Kansas, Lawrence, and colleagues point out that many researchers have focused on natural products – and many pharmaceuticals have resulted from such approaches. Their success is attributed to the diversity of molecular skeletons gleaned from nature, as well as the higher number of sp3 carbon centres present. This endows derivatives with three-dimensional complexity and the chance to fit neatly into specific enzymes, receptors and other proteins involved in disease.

The Kansas team began with selected families of alkaloid natural products, extracted from plants that have a history in folk medicine, as well as molecules with identified medical, insecticidal and other bioactive properties. They began constructing the library based around cut down scaffolds of these alkaloids, using a wide-ranging approach to rapidly synthesise nearly 700 diverse compounds.

By starting with alkaloids, the team hoped that the ‘privileged structures’ of these often toxic but often medicinally active substances would help them home in on useful leads more quickly. The structural characteristics of those compounds nudged them in the right direction. ‘We did try to emphasise sp3 character by choice of the natural products,’ Aubé says. The team carried out a ‘Lipinski’s rule-of-five’ analysis to test how druglike the compounds are, taking in molecular weight, lipophilicity and hydrogen bonding potential. ‘We were a little surprised that the compounds were as highly Lipinski compliant as they turned out to be,’ he adds.

Natural products and their analogues are often too complex for commercially tenable synthesis. This streamlined approach allows Aubé’s team to generate diversity, while maintaining potential drug-like character but keeping the synthetic reaction schemes short. The team obtained up to 90% overall yields on 20mg product scales.

Paul Hergenrother of the University of Illinois recognises the work’s potential: ‘Alkaloids have such a diverse array of bioactivities, and can be active in the central nervous system,’ he says. ‘So, the creation of such a large number (and large diversity) of these compounds is clearly very important. These types of value-added products are likely to be markedly superior – in terms of hit potency and selectivity – to compounds in standard screening collections.’

 


Related Content

Dana Roth: Reaching out from the library

28 October 2014 Research

news image

Caltech’s chemistry librarian chats to Chemistry World about how librarians can support researchers

Chemists cull compounds using ‘intuition’

30 November 2012 Research

news image

Medicinal chemists apparently decided which fragments should be in their screening collection using surprisingly few paramete...

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Spanish fly

10 October 2013 Podcast | Compounds

news image

Helen Scales looks at cantharidin, the active ingredient in this famous aphrodisiac

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Toxicologists enter the fray on endocrine disruptors

29 July 2013 News and Analysis

news image

Open letter urges the European commission to consult with the scientific community before enacting any regulation